“la Caixa” leads €1.6-millions round of funding in Minoryx
<p>The investment has been carried out under the framework of ‘Programa Innvierte’</p>
Through the Caixa Innvierte Biomed II fund, “la Caixa” has led a €1.6-millions round of funding in Minoryx, a company located at the Parc TecnoCampus Mataró-Maresme.
This fund is managed by Caixa Capital Risc, which includes participation of the Center for Industrial Technological Development (CDTI), and the investment has been carried out under the framework of Programa Innvierte with a minority share held by the Catalan Institute of Finance. The Sanfillipo Foundation Switzerland, represented by Daniel Bach, also joined the operation.
Minoryx, headed up by doctors Marc Martinell, Joan Aymamí and Xavier Barril, is devoted to treating minority diseases resulting from congenital metabolic disorders, most of which are currently untreatable. Using their biological screening and computational platform with proprietary technology, called SEE-Tx, the company strives to discover drugs based on small molecules to repair enzyme defects from genetic mutations.